Evidence map›Paper›PMID 35486356›Full record

ArticleInfection2023

SARS-CoV-2 infection in chronic kidney disease patients with pre-existing dialysis: description across different pandemic intervals and effect on disease course (mortality).

Lisa Pilgram, Lukas Eberwein, Bjoern-Erik O Jensen, Carolin E M Jakob, Felix C Koehler, Martin Hower, Jan T Kielstein, Melanie Stecher, Bernd Hohenstein, Fabian Prasser and 6 more

Abstract readMulticenter Study
In one paragraph

Article in Infection, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Post-COVID-19 inflammation and sarcopenia in obese diabetic dialysis patients.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Lisa PilgramDepartment of Nephrology and Medical Intensive Care, Charité, Universitätsmedizin Berlin, Berlin, Germany.
Lukas Eberwein4th Department of Internal Medicine, Klinikum Leverkusen gGmbH, Leverkusen, Germany.
Bjoern-Erik O JensenDepartment of Gastroenterology, Hepatology and Infectious Diseases, Heinrich Heine University, Düsseldorf, Germany.
Carolin E M JakobDepartment I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Felix C KoehlerDepartment II of Internal Medicine and Center for Molecular Medicine Cologne, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Martin HowerDepartment of Pneumology, Infectiology, Internal Medicine and Intensive Care, Klinikum Dortmund gGmbH, Dortmund, Hospital of University Witten/Herdecke, Dortmund, Germany.
Jan T KielsteinMedical Clinic V, Nephrology|Rheumatology|Blood Purification, Academic Teaching Hospital Braunschweig, Braunschweig, Germany.
Melanie StecherDepartment I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Bernd HohensteinNephrological Centre Villingen-Schwenningen, Villingen-Schwenningen, Germany.
Fabian PrasserBerlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
Timm WesthoffDepartment of Internal Medicine I, Marien Hospital Herne Ruhr University Bochum, Herne, Germany.
Susana M Nunes de MirandaDepartment I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Maria J G T VehreschildDepartment of Internal Medicine, Infectious Diseases, Goethe University Frankfurt, Frankfurt, Germany.
Julia LanznasterDepartment of Internal Medicine 2, Klinikum Passau, Passau, Germany.
Sebastian DolffDepartment of Infectious Diseases, West German Centre of Infectious Diseases, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45122, Essen, Germany. sebastian.dolff@uk-essen.de.ORCID http://orcid.org/0000-0001-5549-1706
LEOSS study group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePatients suffering from chronic kidney disease (CKD) are in general at high risk for severe coronavirus disease (COVID-19) but dialysis-dependency (CKD5D) is poorly understood. We aimed to describe CKD5D patients in the different intervals of the pandemic and to evaluate pre-existing dialysis dependency as a potential risk factor for mortality.

methodsIn this multicentre cohort study, data from German study sites of the Lean European Open Survey on SARS-CoV-2-infected patients (LEOSS) were used. We multiply imputed missing data, performed subsequent analyses in each of the imputed data sets and pooled the results. Cases (CKD5D) and controls (CKD not requiring dialysis) were matched 1:1 by propensity-scoring. Effects on fatal outcome were calculated by multivariable logistic regression.

resultsThe cohort consisted of 207 patients suffering from CKD5D and 964 potential controls. Multivariable regression of the whole cohort identified age (> 85 years adjusted odds ratio (aOR) 7.34, 95% CI 2.45-21.99), chronic heart failure (aOR 1.67, 95% CI 1.25-2.23), coronary artery disease (aOR 1.41, 95% CI 1.05-1.89) and active oncological disease (aOR 1.73, 95% CI 1.07-2.80) as risk factors for fatal outcome. Dialysis-dependency was not associated with a fatal outcome-neither in this analysis (aOR 1.08, 95% CI 0.75-1.54) nor in the conditional multivariable regression after matching (aOR 1.34, 95% CI 0.70-2.59).

conclusionsIn the present multicentre German cohort, dialysis dependency is not linked to fatal outcome in SARS-CoV-2-infected CKD patients. However, the mortality rate of 26% demonstrates that CKD patients are an extreme vulnerable population, irrespective of pre-existing dialysis-dependency.

Indexed as

COVID-19Renal Insufficiency, ChronicAged, 80 and overCohort StudiesDisease ProgressionHumansPandemicsRenal DialysisSARS-CoV-2CKD5DCOVID-19HemodialysisKidneySARS-CoV-2

Identifiers

PMID35486356
PMCPMC9052729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.